Method of isolating and detecting exosomal biomarkers of glioblastoma malignancy
AssigneeCity University of Hong Kong
InventorsAbhimanyu Thakur, Wing Kar Li, Youngjin Lee
Life of this patent
Estimating the term…
Abstract
Disclosed herein is a method of diagnosing a malignant glioblastoma. The method can comprise of isolating glioma-derived exosomes from a bodily fluid of the subject, and characterizing the amount of Cluster of Differentiation (CD44) and Cluster of Differentiation 133 (CD133) present in the glioma-derived exosomes. This method allows for the diagnosis of a malignant glioblastoma using CD44 and CD133 levels in EGFRviii specific immunocaptured exosomes from bodily fluids, which has previously not been recognized as providing an indication of a glioblastoma.
Claims1
A method of identifying and treating a subject having glioblastoma comprising:
- (a) identifying the subject by,
- (i) obtaining a sample of blood or cerebrospinal fluid-derived extracellular vesicles (EVs) from the subject;
- (ii) mixing the sample with a plurality of streptavidin-coated magnetic beads so as to separate Epidermal Growth Factor Receptor Variant-III (EGFRviii)-containing EVs from the sample, wherein, each streptavidin-coated magnetic bead is further linked with biotin, which is in turn bound to an anti-EGFRviii antibody;
- separating the EGFRviii-containing EVs from the sample by,
- (ii-1) using a magnet to move the streptavidin-coated magnetic beads bound EGFRviii-containing EVs away from the sample;
- (ii-2) using a release buffer solution to break the bonding between the EGFRviii-containing EVs and the anti-EGFRviii antibody on the streptavidin-coated magnetic beads;
- and
- (ii-3) using the magnet to remove the streptavidin-coated magnetic beads from the EGFRviii-containing EVs,
- (iii) affixing the separated EGFRviii-containing EVs on a titanium nitride substrate having a layer of biotinylated Cluster of Differentiation (CD) 63 antibody coated thereon, in which the separated EGFRviii-containing EVs are affixed on the titanium nitride substrate via the attraction between CD63 of the separated EGFRviii-containing EVs and the biotinylated CD63 antibody;
- and
- (iv) characterizing the expression of CD44 and CD133 on the separated EGFRviii-containing EVs via surface plasmonic resonance or atomic force microscopy;
- and
- (b) administering a treatment to the subject when the expression of CD44 and CD133 are found on the separated EGFRviii-containing EVs in step (a), wherein the treatment is selected from the group consisting of chemotherapy, radiation, surgery, and a combination thereof.
Dependencies are inferred from the claim text.